Allarity Therapeutics, Inc.
ALLR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001860657
No open-market purchases or sales by Allarity Therapeutics, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Allarity Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 6 | 9 | +3 |
| Shares | 104.5K | 92.4K | −12.1K (−11.6%) |
| Value | $122.3K | $86.5K | −$35.7K (−29.2%) |
New holders (6)
Institutions that held Allarity Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 33,921 | $31.8K | 0.00% |
| Morgan Stanley | 23,311 | $21.8K | 0.00% |
| Corsair Capital Management, L.P. | 20,000 | $18.7K | 0.00% |
| Barclays PLC | 10,078 | $9.44K | 0.00% |
| UBS Group AG | 300 | $281 | 0.00% |
| Advisor Group Holdings, Inc. | 7 | $6 | 0.00% |
Sold out (3)
Institutions that held Allarity Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Stonepine Capital Management, LLC | 67,289 | $78.7K |
| Goldman Sachs Group Inc | 20,616 | $24.1K |
| Citigroup Inc | 12,294 | $14.4K |